Case Report| Volume 14, ISSUE 4, e431-e434, August 2016

Anti-programmed Death Receptor 1 Blockade Induces Clinical Response in a Patient With Metastatic Collecting Duct Carcinoma

Published:February 23, 2016DOI:
      Collecting duct carcinoma (CDC) is a very rare subtype of renal cell carcinoma (RCC), accounting for < 2% of all cases of RCC and associated with a very poor prognosis.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Grabowski M.
        • Huzarski T.
        • Lubinski J.
        • Sikorski A.
        Survival in patients with rare subtypes of renal cell carcinoma.
        BJU Int. 2002; 89: 599-600
        • Chao D.
        • Zisman A.
        • Pantuck A.J.
        • et al.
        Collecting duct renal cell carcinoma: clinical study of a rare tumor.
        J Urol. 2002; 167: 71-74
        • Dason S.
        • Allard C.
        • Sheridan-Jonah A.
        • et al.
        Management of renal collecting duct carcinoma: a systematic review and the McMaster experience.
        Curr Oncol. 2013; 20: e223-e232
        • Sankin A.
        • Hakimi A.A.
        • Hsieh J.J.
        • Molina A.M.
        Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.
        Front Oncol. 2015; 5: 67
        • Brahmer J.R.
        • Drake C.G.
        • Wollner I.
        • et al.
        Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
        J Clin Oncol. 2010; 28: 3167-3175
        • Motzer R.J.
        • Escudier B.
        • McDermott D.F.
        • et al.
        Nivolumab versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1803-1813
        • Valenca L.B.
        • Hirsch M.S.
        • Choueiri T.K.
        • Harshman L.C.
        Non-clear cell renal cell carcinoma, part 2: therapy.
        Clin Adv Hematol Oncol. 2015; 13: 383-391
        • Thompson R.H.
        • Gillett M.D.
        • Cheville J.C.
        • et al.
        Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target.
        Proc Natl Acad Sci U S A. 2004; 101: 17174-17179
        • Choueiri T.K.
        • Fay A.P.
        • Gray K.P.
        • et al.
        PD-L1 expression in nonclear-cell renal cell carcinoma.
        Ann Oncol. 2014; 25: 2178-2184